Medical Transcatheter Aortic Valve Fares Well in Clinical Study

Published date : 06 November 2012
Article date : 06 November 2012

Medgadget reports on promising results arising from a clinical study of Direct Flow Medical's Transcatheter Aortic Valve System. They say that the device achieved its primary mortality endpoint and that over 95% of patients had mild or less aortic regurgitation. No patients experienced vascular complications.

The valve is made of a polymer frame, bovine pericardium leaflets and 2 inflatable rings that sit on both sides of the patient’s own valve. The rings can also deflate and the valve can be repositioned for a better fit or removed if complications occur.

The system is delivered endovascularly via an 18F introducer sheath. Apparently, during the trial, all patients were successfully treated via a transfemoral approach using Direct Flow Delivery System. The primary endpoin - freedom from all-cause mortality from procedure to 30 days - was met at 97%. Freedom from all cause cardiovascular mortality at 30 days was 100%. they say that the valve resulted in 97% mild or less aortic regurgitation.

Source:, 02 November 2012.

Read the full article here

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.